Alcon withdraws all CyPass micro-stents, says it will not affect spin-off

This article was originally published here

Novartis (NYSE:NVS)’s Alcon said this week it is voluntarily withdrawing its CyPass micro-stents from the global market, but that the withdrawal will not affect its planned spin-out.

The decision to pull the devices comes off the analysis of five-year post-surgery data from the Compass-XT study of the device, which showed that patients treated with the stent had statistically significant loss of endothelial cells as compared to a control group. Endothelial cells are believed to be vital in maintaining visual functionality.

The company advised surgeons to immediately cease further implantation of the devices and return any unused devices to Alcon, and added that it will be communicating with surgeons with recommendations for evaluating and managing patients who have already been implanted with the device.

“We believe that withdrawing the CyPass micro-stent from the market is in patients’ best interest and is the right thing to do. Although we are removing the product from the market now out of an abundance of caution, we intend to partner with the FDA and other regulators to explore labeling changes that would support the reintroduction of the CyPass Micro-Stent in the future,” chief medical officer Dr. Stephen Lane said in a press release.

The withdrawal won’t affect Alcon’s planned spin-off from Novartis, according to a Reuters report, and should be immaterial to the company’s total sales.

Novartis’ Alcon won FDA clearance for the CyPass micro-stent, with indications for reducing intraocular pressure in patients suffering from glaucoma, in July 2016.

The post Alcon withdraws all CyPass micro-stents, says it will not affect spin-off appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply